Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (NCT06631287)
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC)
🩺 Plain-English Summary (8th-Grade Level)
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.
Who can join: Review the eligibility criteria below.
Location: University of Arizona — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- University of Arizona — Tucson, Arizona
- University of California, Los Angeles (UCLA) — Los Angeles, California
- University of California San Francisco — San Francisco, California
- University of Colorado I Anschutz Medical Campus — Aurora, Colorado
- Yale University — New Haven, Connecticut
- University of Florida College of Medicine — Gainesville, Florida
- Emory University — Atlanta, Georgia
- Illinois Research Network (ILLInet), University of Illinois Chicago — Chicago, Illinois
- Brigham and Women's Hospital — Boston, Massachusetts
- University of Minnesota — Minneapolis, Minnesota
- NYU Langone Health - Brooklyn — Brooklyn, New York
- University Hospitals Cleveland Case Western — Cleveland, Ohio
- The MetroHealth System — Cleveland, Ohio
- Vanderbilt University Medical — Nashville, Tennessee
- University of Texas at San Antonio — San Antonio, Texas
- Swedish Medical Center — Seattle, Washington
- West Virginia Clinical and Translational Science Institute — Morgantown, West Virginia
📞 Contact the Study Coordinator
Phone: (615) 343-8010
Email: vccrvlcstudy@vumc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Long COVID
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID — San Francisco, California
- The Long COVID Treatment Trial — La Jolla, California
- tVNS in Long COVID-19 — New York, New York
- Nutritional Management of Post COVID-19 Cognitive Symptoms — Edmonton, Alberta
- Pain in Long COVID-19: the Role of Sleep — Boston, Massachusetts
- Long COVID Immune Profiling — Nashville, Tennessee
Explore by condition: All Long COVID clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.